Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NLY01 in Type 2 Diabetes
NCT04159766Phase 2Completed
- Sponsor
- Neuraly
- Start
- Oct 2019
- Primary completion
- Dec 2020
- Modality
- Polymer-based Nanoparticles, Modified Peptides, Native Peptides
- Countries
- 1
01
Overview
A Phase 2 trial of pegsebrenatide in type 2 diabetes mellitus (T2DM), sponsored by Neuraly. Started Oct 2019; status: completed.
02
Drugs
pegsebrenatide
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT04159766.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04159766.